Evaluation of a New Cardiac Biomarker Assay

Phase 3

Completed

• Conditions: Acute Coronary Syndrome; Acute Myocardial Infarction
• Interventions: Device: ARCHITECT STAT High Sensitive Troponin I Assay

• Registration Number: NCT01608100
• Lead Sponsor: Abbott Diagnostics Division

Brief Summary

The objective of the study is to evaluate the performance and intended use of a new cardiac biomarker test, Troponin I, in an intended use population. Blood specimens will be tested using the new investigational test that detects the level of Troponin I. Results will be compared to the diagnosis of whether or not an acute myocardial infarction (MI) occurred.

Detailed Description

The purpose of the cardiac biomarker Troponin I is to aid in the diagnosis of myocardial infarction.The assay is also intended to assist in the prognosis relative risk to all cause mortality (ACM) and major adverse cardiac events (MACE) consisting of myocardial infarction, revascularization, and cardiac death in patients who present with symptoms suggestive of acute coronary syndrome (ACS) without a diagnosis of myocardial infarction.

All specimens were collected under a separate specimen collection protocol (Protocol No, 7B5-02-09A01-01: Clinical Specimen Procurement for Biomarker Evaluation of Suspected ACS). The specimens that will be tested include approximately 8300 specimens collected from 1101 subjects presenting to Emergency Departments with signs and symptoms of Acute Coronary Syndrome and will be provided to the clinical sites performing investigational Troponin I testing.

Study Timeline

• Study First Submitted: 2012-05-21
• Study First Submitted QC: 2012-05-29
• Study First Posted: 2012-05-30
• Study Start: 2012-06
• Primary Completion: 2014-08
• Study Completion: 2014-09
• Results First Submitted: 2014-12-03
• Status Verified: 2015-01
• Results First Submitted QC: 2015-03-04
• Last Update Submitted: 2015-03-04
• Results First Posted: 2015-03-17
• Last Update Posted: 2015-03-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1101

Inclusion Criteria

• presenting to the Emergency Department with symptoms consistent with or suggestive of Acute Coronary Syndrome (ACS) defined as at least 5 minutes of chest pain (or symptoms consistent with myocardial ischemia) up to 6 hours prior to initial evaluation.
• an Electrocardiogram (ECG) result within 2 hours of presentation for observation of Acute Coronary Syndrome (ACS).
• greater than 18 years of age.
• not known to be pregnant.
• agreement to the follow-up required by the study.

Exclusion Criteria

• prior participation in this study.
• require dialysis for end stage renal disease.
• history of a previous heart transplant.
• coexisting disorder associated with limited life expectancy.
• currently participating in another investigational device or drug study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ARCHITECT STAT High Sensitive Troponin I Assay testing	ARCHITECT STAT High Sensitive Troponin I Assay	All subjects will have their blood tested by the investigational ARCHITECT STAT High SensitiveTroponin I assay.

Primary Outcome Measures

Name	Time	Method
Clinical Performance - Area Under the Curve	Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department	The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating the Area Under the Curve (AUC). The Area Under the Curve that was assessed, is used to determine the optimum clinical sensitivity and specificity for the ARCHITECT STAT High Sensitive Troponin-I assay. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).
Clinical Performance- Sensitivity	Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department	The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Sensitivity. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).
Clinical Performance- Specificity	Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department.	The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Specificity. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).
Clinical Performance- Negative Predictive Value (NPV)	Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department.	The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Negative Predictive Value. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).
Clinical Performance- Positive Predictive Value (PPV)	Troponin value from three collection time points (0-2 hours, >2 and up to 4 hours, >4 hours and up to 9 hours) from subject presentation to the emergency department.	The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating the Positive Predictive Value. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).

Secondary Outcome Measures

Name	Time	Method
Prognosis	30-day and 90-day follow-up	Specimens were collected at 11 EDs from 1,101 subjects presenting to the ED with symptoms consistent with ACS. All subject diagnoses were adjudicated by three board certified cardiologists according to current standard of care. ARCHITECT STAT High Sensitive Troponin I results were generated from subject specimens and evaluated for use as an aid in the assessment of prognosis. Analyses used the first available troponin result from multiple serial draw time points. Subjects were assessed for risk of all cause mortality (ACM) and major adverse cardiac event (MACE) at 30 day and 90 day time points after ED discharge. MACE consisted of myocardial infarction, urgent revascularization, and cardiac death. Subjects were followed-up for subsequent events by medical record review and/or subject/caregiver contact. Any ACM and MACE that occurred during the ED visit and on the same day as ED discharge were not included in the analyses.

Trial Locations

Locations (11)

Stanford University School of Emergency Medicine; 🇺🇸 Palo Alto, California, United States

Chandler Regional Medical Center; 🇺🇸 Chandler, Arizona, United States

Hospital Physicians in Clinical Research; 🇺🇸 Bryan, Texas, United States

Pennsylvania State University- Hershey Medical Center; 🇺🇸 Hershey, Pennsylvania, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Nationwide Laboratory Services; 🇺🇸 Fort Lauderdale, Florida, United States

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States

John T Mather Memorial Hospital; 🇺🇸 Port Jefferson, New York, United States

St Joseph Hospital; 🇺🇸 Bellingham, Washington, United States

Dept of Emergency Medicine University of Virginia; 🇺🇸 Charlottesville, Virginia, United States

Hospital of the University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States